Raras
Buscar doenças, sintomas, genes...
Neoplasias endócrinas múltiplas tipo 2
ORPHA:653CID-10 · D44.8CID-11 · 2F7A.0DOENÇA RARA

A neoplasia endócrina múltipla tipo 2 (NEM2) é uma neoplasia endócrina múltipla, uma síndrome de câncer poliglandular caracterizada pela ocorrência de carcinoma medular de tireoide (CMT), feocromocitoma (PCC), em uma variante, o hiperparatireoidismo primário (HPTP). Existem três formas: MEN2A, MEN2B e carcinoma medular familiar da tireoide (FMTC).

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

A neoplasia endócrina múltipla tipo 2 (NEM2) é uma neoplasia endócrina múltipla, uma síndrome de câncer poliglandular caracterizada pela ocorrência de carcinoma medular de tireoide (CMT), feocromocitoma (PCC), em uma variante, o hiperparatireoidismo primário (HPTP). Existem três formas: MEN2A, MEN2B e carcinoma medular familiar da tireoide (FMTC).

Pesquisas ativas
4 ensaios
17 total registrados no ClinicalTrials.gov
Publicações científicas
862 artigos
Último publicado: 2026 Mar 20

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-9 / 100 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
2.9
Europe
Início
Adolescent
+ adult, childhood, infancy
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: D44.8
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🦴
Ossos e articulações
9 sintomas
📏
Crescimento
8 sintomas
🧠
Neurológico
8 sintomas
🫘
Rins
7 sintomas
🫃
Digestivo
6 sintomas
😀
Face
3 sintomas

+ 22 sintomas em outras categorias

Características mais comuns

90%prev.
Carcinoma medular de tireoide
Muito frequente (99-80%)
55%prev.
Hipertensão associada a feocromocitoma
Frequente (79-30%)
55%prev.
Catecolaminas urinárias elevadas
Frequente (79-30%)
55%prev.
Neoplasia cervical
Frequente (79-30%)
55%prev.
Hiperidrose
Frequente (79-30%)
55%prev.
Diarreia
Frequente (79-30%)
71sintomas
Muito frequente (1)
Frequente (18)
Ocasional (26)
Muito raro (3)
Sem dados (23)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 71 características clínicas mais associadas, ordenadas por frequência.

Carcinoma medular de tireoideMedullary thyroid carcinoma
Muito frequente (99-80%)90%
Hipertensão associada a feocromocitomaHypertension associated with pheochromocytoma
Frequente (79-30%)55%
Catecolaminas urinárias elevadasElevated urinary catecholamines
Frequente (79-30%)55%
Neoplasia cervicalCervical neoplasm
Frequente (79-30%)55%
HiperidroseHyperhidrosis
Frequente (79-30%)55%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico862PubMed
Últimos 10 anos200publicações
Pico202530 papers
Linha do tempo
2026Hoje · 2026🧪 1991Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

3 genes identificados com associação a esta condição. Padrão de herança: Autosomal dominant.

RETProto-oncogene tyrosine-protein kinase receptor RetDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Receptor tyrosine-protein kinase involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation in response to glia cell line-derived growth family factors (GDNF, NRTN, ARTN, PSPN and GDF15) (PubMed:20064382, PubMed:20616503, PubMed:20702524, PubMed:21357690, PubMed:21454698, PubMed:24560924, PubMed:28846097, PubMed:28846099, PubMed:28953886, PubMed:31118272). In contrast to most receptor tyrosine kinases, RET requires not onl

LOCALIZAÇÃO

Cell membraneEndosome membrane

VIAS BIOLÓGICAS (4)
RET signalingFormation of the ureteric budFormation of the nephric ductNPAS4 regulates expression of target genes
MECANISMO DE DOENÇA

Hirschsprung disease 1

A disorder of neural crest development characterized by absence of enteric ganglia along a variable length of the intestine. It is the most common cause of congenital intestinal obstruction. Early symptoms range from complete acute neonatal obstruction, characterized by vomiting, abdominal distention and failure to pass stool, to chronic constipation in the older child.

EXPRESSÃO TECIDUAL(Tecido-específico)
Substância negra
6.3 TPM
Pituitária
4.8 TPM
Cerebelo
4.0 TPM
Cólon sigmoide
4.0 TPM
Brain Frontal Cortex BA9
3.8 TPM
OUTRAS DOENÇAS (12)
multiple endocrine neoplasia type 2Bpheochromocytomafamilial medullary thyroid carcinomamultiple endocrine neoplasia type 2A
HGNC:9967UniProt:P07949
NTRK1High affinity nerve growth factor receptorCandidate gene tested inTolerante
FUNÇÃO

Receptor tyrosine kinase involved in the development and the maturation of the central and peripheral nervous systems through regulation of proliferation, differentiation and survival of sympathetic and nervous neurons. High affinity receptor for NGF which is its primary ligand (PubMed:1281417, PubMed:15488758, PubMed:17196528, PubMed:1849459, PubMed:1850821, PubMed:22649032, PubMed:27445338, PubMed:8325889). Can also bind and be activated by NTF3/neurotrophin-3. However, NTF3 only supports axon

LOCALIZAÇÃO

Cell membraneEarly endosome membraneLate endosome membraneRecycling endosome membrane

VIAS BIOLÓGICAS (1)
TRKA activation by NGF
MECANISMO DE DOENÇA

Congenital insensitivity to pain with anhidrosis

Characterized by a congenital insensitivity to pain, anhidrosis (absence of sweating), absence of reaction to noxious stimuli, self-mutilating behavior, and intellectual disability. This rare autosomal recessive disorder is also known as congenital sensory neuropathy with anhidrosis or hereditary sensory and autonomic neuropathy type IV or familial dysautonomia type II.

EXPRESSÃO TECIDUAL(Tecido-específico)
Próstata
5.7 TPM
Testículo
4.9 TPM
Cervix Endocervix
4.3 TPM
Útero
3.7 TPM
Fallopian Tube
3.5 TPM
OUTRAS DOENÇAS (4)
hereditary sensory and autonomic neuropathy type 4hereditary sensory and autonomic neuropathy type 5familial medullary thyroid carcinomadifferentiated thyroid carcinoma
HGNC:8031UniProt:P04629
ESR2Estrogen receptor betaCandidate gene tested inTolerante
FUNÇÃO

Nuclear hormone receptor. Binds estrogens with an affinity similar to that of ESR1/ER-alpha, and activates expression of reporter genes containing estrogen response elements (ERE) in an estrogen-dependent manner (PubMed:20074560) Lacks ligand binding ability and has no or only very low ERE binding activity resulting in the loss of ligand-dependent transactivation ability

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (4)
PI5P, PP2A and IER3 Regulate PI3K/AKT SignalingPIP3 activates AKT signalingConstitutive Signaling by Aberrant PI3K in CancerExtra-nuclear estrogen signaling
MECANISMO DE DOENÇA

Ovarian dysgenesis 8

An autosomal dominant form of ovarian dysgenesis, a disorder characterized by lack of spontaneous pubertal development, primary amenorrhea, uterine hypoplasia, and hypergonadotropic hypogonadism as a result of streak gonads.

EXPRESSÃO TECIDUAL(Baixa expressão)
Ovário
4.6 TPM
Testículo
3.9 TPM
Glândula adrenal
3.6 TPM
Linfócitos
2.3 TPM
Cervix Endocervix
1.4 TPM
OUTRAS DOENÇAS (2)
ovarian dysgenesis 8familial medullary thyroid carcinoma
HGNC:3468UniProt:Q92731

Medicamentos aprovados (FDA)

1 medicamento encontrado nos registros da FDA americana.

💊 Famotidine (FAMOTIDINE)
Ver no DailyMed/FDA

Variantes genéticas (ClinVar)

832 variantes patogênicas registradas no ClinVar.

🧬 RET: NM_020975.6(RET):c.2940-1G>A ()
🧬 RET: NM_020975.6(RET):c.206del (p.Gly69fs) ()
🧬 RET: NM_020975.6(RET):c.3039+1G>A ()
🧬 RET: NM_020975.6(RET):c.1658G>T (p.Arg553Met) ()
🧬 RET: NM_020975.6(RET):c.249C>A (p.Asn83Lys) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 3,225 variantes classificadas pelo ClinVar.

161
1451
1613
Patogênica (5.0%)
VUS (45.0%)
Benigna (50.0%)
VARIANTES MAIS SIGNIFICATIVAS
RET: NM_020975.6(RET):c.2940-1G>A [Likely pathogenic]
RET: NM_020975.6(RET):c.1685C>G (p.Thr562Ser) [Uncertain significance]
RET: NM_020975.6(RET):c.574C>T (p.Pro192Ser) [Uncertain significance]
RET: NM_020975.6(RET):c.603C>A (p.Ser201Arg) [Uncertain significance]
RET: NM_020975.6(RET):c.1082A>G (p.Asn361Ser) [Uncertain significance]

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
2Fase 22
1Fase 11
·Pré-clínico6
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 9 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Neoplasias endócrinas múltiplas tipo 2

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

3 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

17 ensaios clínicos encontrados, 4 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

💬Melhor nível de evidência: Opinião
Timeline de publicações
251 papers (10 anos)
#1

How has genetics changed the diagnosis and care of multiple endocrine neoplasia type 2? The merits and pitfalls of a genetic-based diagnostic and therapeutic approach.

Annales d'endocrinologie2026 Mar 20

The discovery of RET as the primary driver of hereditary medullary thyroid cancer in multiple endocrine neoplasia syndrome drastically changed the diagnosis, management, and prognosis of patients with this rare endocrine tumor. First, from a diagnostic viewpoint, RET testing within families became possible, ruling out unnecessary follow-up for negative patients and proposing an adapted surveillance protocol for positive patients. Second, large-scale epidemiological studies paved the way for early "prophylactic" thyroidectomy, rendering a historically fatal disease curable. RET identification also allowed for proper screening of pheochromocytoma and primary hyperparathyroidism. Lastly, RET identification enabled the synthesis of new, highly effective, and well-tolerated specific inhibitors, which changed the outcome for patients with metastatic disease. The RET discovery is thus a perfect example of how gene discovery can transform the fate of a rare syndrome, and this is what will be described in this short review.

#2

Advanced disease and biochemical phenotype shift in multiple endocrine neoplasia type 2A-related pheochromocytoma.

JCEM case reports2026 Mar

The incidence of metastatic recurrence in multiple endocrine neoplasia type 2 (MEN2)-related pheochromocytoma is low, and reports are scarce. Moreover, there are no reports detailing changes in biochemical findings at the time of metastatic recurrence. We describe here the case of a woman in her 40s with MEN2-related pheochromocytoma. She exhibited an increase in spot urine normetanephrine levels 2 years and 8 months after laparoscopic right adrenalectomy for right pheochromocytoma, leading to the diagnosis of peritoneal dissemination and distant metastasis. She underwent chemotherapy, which was ineffective, and died 3 years and 2 months after the initial surgery. Metastasis and recurrence of MEN2-related pheochromocytoma are rare, and a change in the biochemical phenotype is also uncommon. Therefore, we report the clinical course of this case in detail.

#3

Systematic structure-based analysis of RET variants in MEN2A, Hirschsprung's disease, and their paradoxical co-occurrence.

Disease models &amp; mechanisms2026 Mar 12

Mutations in the human receptor tyrosine kinase RET can cause loss-of-function and Hirschsprung's disease (HSCR), while activating RET mutations drive cancers including multiple endocrine neoplasia type 2 (MEN2). Paradoxically, some mutations cause both HSCR and MEN2A. We curated 77 RET extracellular positions associated with HSCR, MEN2A, or both and used a structure-based approach to predict the effects of mutations at these positions on RET structure. Approximately 90% of HSCR-associated positions can, upon mutation, disrupt intramolecular interactions stabilizing RET tertiary structure via distinct mechanisms. Only a minority perturb protein-protein interactions needed for signal activation. In contrast, our analysis showed that ∼75% of mutations causing MEN2A lead to an unpaired cysteine that can form an intermolecular disulfide bond between two RET monomers. Other MEN2A mutations likely enhance RET homodimerization via membrane-proximal extracellular interactions. Substitutions that concurrently destabilize RET structure and result in an unpaired cysteine are predicted to cause the paradoxical co-occurrence of HSCR and MEN2A. Our findings lay out a mechanistic basis for almost all identified pathological RET mutations and suggest therapeutic strategies for targeting RET activity in HSCR and MEN2A.

#4

Bilateral pheochromocytoma: case series and review of treatment strategies based on genetic mutations.

Translational andrology and urology2026 Feb 28

Recent genetic analyses have revealed that bilateral pheochromocytoma (PCC) is more frequently associated with hereditary syndromes, such as von Hippel-Lindau (VHL) disease and multiple endocrine neoplasia type 2 (MEN2), than previously recognized. Although bilateral adrenalectomy has traditionally been considered the standard treatment for bilateral PCC, it inevitably results in permanent adrenal insufficiency, requiring lifelong steroid replacement and increasing the risk of adrenal crisis. As an alternative strategy, adrenal-sparing surgery has been proposed to preserve adrenal function; however, concerns remain regarding the risk of tumor recurrence in the remnant adrenal tissue. We report four cases of bilateral PCC treated with adrenal-sparing surgery at The Jikei University Hospitals. Adrenal-sparing surgery was successfully attempted in all patients, and all avoided long-term steroid dependence. Genetic testing confirmed VHL disease in one patient in the overall cohort. Based on family history and clinical features, VHL disease was suspected in one additional patient, and MEN2 was suspected in two patients. Based on our experience and a review of the literature, adrenal-sparing surgery allows preservation of adrenal function and can eliminate the need for postoperative steroid replacement in many patients with bilateral PCC. Although the risk of recurrence in the residual adrenal gland may be higher than that after total adrenalectomy, recurrence at other sites and overall mortality appear comparable between the two surgical approaches. Therefore, adrenal-sparing surgery represents a valuable surgical option in carefully selected patients. Furthermore, recent studies have identified pathogenic mutations in several genes associated with bilateral PCC, with incidence and prognosis varying according to genetic background. Gene mutations are more likely in younger patients, those with tumors ≥5 cm, paragangliomas (PGLs), norepinephrine-secreting tumors lacking epinephrine production, and individuals with known hereditary syndromes, who also exhibit a higher risk of recurrence. Accordingly, current guidelines recommend lifelong surveillance and individualized management based on genetic and clinical factors.

#5

Rare cases in two Chinese MEN2A families with RET C634Y germline mutation-a homozygous female patient and heterozygous identical twins: a systematic review of literature.

Frontiers in endocrinology2026

Germline RET-p.C634Y heterozygous mutations are predominant in MEN2A, but homozygous cases and MEN2A-affected identical twins remain poorly characterized. We report two MEN2A families-a homozygous female patient and heterozygous male twins, all with RET-p.C634Y mutations and classic MEN2A manifestations. A systematic review identified 18 homozygous cases from 10 families, involving exons 11, 14, and 15, containing nine types of mutations, presenting a female (55.6%) and moderate-risk mutation (61.1%) predominance. Overall, 83.3% of the 18 patients with homozygous mutations and 30.6% of the 49 patients with heterozygous mutations from the same generation had medullary thyroid carcinoma (MTC). The homozygous mutations had a higher penetrance rate of MTC (P < 0.001) and rates of node-positive metastasis (8/15 vs. 1/15, P = 0.017). However, the comparison of the mean age at initial MTC diagnosis between patients with homozygous and heterozygous mutations [33.40 ± 17.97 (5-59) vs. 39.60 ± 12.94 (14-61) years], as well as in moderate-risk and high-risk patients with homozygous mutations [36.89 ± 16.21 (13-59) vs. 28.17 ± 20.72 (5-56) years], showed no significant differences (all P > 0.05). Additionally, the mean age at diagnosis and the incidence of pheochromocytoma did not differ significantly [(37.75 ± 18.43) vs. (39.5 ± 3.54); 27.8% vs. 13.3%; all P > 0.05]. Clustered data for identical twins diagnosed with MEN2 were also analyzed, including one with MEN2A and two with MEN2B. All three pairs of identical twins exhibited varying clinical presentations, expressivity of MEN2-related MTC and/or pheochromocytoma, and associated biomarker levels. Homozygous MEN2A accelerates MTC onset and increases metastasis risk, but there is no evidence of association with the development of pheochromocytoma. Consanguineous marriage could increase homozygosity in offspring and the number of affected individuals. Expressivity and clinical progression can vary even with the same genetic backgrounds, and identical twins should also be subject to individual management.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC278 artigos no totalmostrando 198

2026

How has genetics changed the diagnosis and care of multiple endocrine neoplasia type 2? The merits and pitfalls of a genetic-based diagnostic and therapeutic approach.

Annales d'endocrinologie
2026

Advanced disease and biochemical phenotype shift in multiple endocrine neoplasia type 2A-related pheochromocytoma.

JCEM case reports
2026

Systematic structure-based analysis of RET variants in MEN2A, Hirschsprung's disease, and their paradoxical co-occurrence.

Disease models &amp; mechanisms
2026

Bilateral pheochromocytoma: case series and review of treatment strategies based on genetic mutations.

Translational andrology and urology
2026

Rare cases in two Chinese MEN2A families with RET C634Y germline mutation-a homozygous female patient and heterozygous identical twins: a systematic review of literature.

Frontiers in endocrinology
2026

Incretin Mimetics in Cancer and Cardiovascular Disease: JACC: CardioOncology State-of-the-Art Review.

JACC. CardioOncology
2026

Rare RET Variants in a Patient With MEN2A and Multiple Follicular-Derived Thyroid Tumors: A Case Report and Review of the Literature.

International journal of surgical pathology
2026

RET germline mutations drive tumorigenesis but not tumor aggressiveness in MEN 2.

Endocrine
2026

Calcitonin Thresholds for Prediction of Medullary Thyroid Carcinoma and its Clinical Response in MEN2A Gene Carriers.

The Journal of clinical endocrinology and metabolism
2026

Efficacy and safety of pralsetinib in multiple endocrine neoplasia type 2-associated pheochromocytoma: a case report.

Therapeutic advances in endocrinology and metabolism
2025

Utility of in Vivo Corneal Confocal Microscopy in Atypical MEN2B Findings. A Case Report.

Ceska a slovenska oftalmologie : casopis Ceske oftalmologicke spolecnosti a Slovenske oftalmologicke spolecnosti
2026

Redefining the prevalence of different clinical variants in MEN2A and their correlation with RET germline mutations: a single-center series and experience.

Endocrine-related cancer
2025

Presentation of multiple endocrine neoplasia type 2A-associated ectopic cushing's syndrome: case report and a systematic review.

Frontiers in endocrinology
2024

CLINICAL EVALUATION, DIAGNOSIS AND TREATMENT OF PHEOCHROMOCYTOMA.

Acta clinica Croatica
2026

Medullary thyroid carcinoma exclusively associated with a homozygous RET V778I pathogenic variant: a case report with review of literature.

Endocrine journal
2025

A Case of Micro-medullary Thyroid Carcinoma Presenting as Cancer of Unknown Primary.

Cureus
2025

Inhibitory Effects of Vandetanib on Catecholamine Synthesis in Rat Pheochromocytoma PC12 Cells.

International journal of molecular sciences
2025

When Diarrhea Tells a Deeper Story: A Curious Case of Metastatic Medullary Thyroid Carcinoma.

Cureus
2025

Contribution of Germline Predisposition to Pediatric Thyroid Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research
2025

Medullary Thyroid Cancer Risk and Mortality in Carriers of Incidentally Identified MEN2A RET Variants.

JAMA network open
2025

Four decades of the RET gene: From discovery to tumor-agnostic therapy.

Journal of the Formosan Medical Association = Taiwan yi zhi
2025

Double mutation for multiple endocrine neoplasia associated with congenital adrenal hyperplasia.

Endocrinology, diabetes &amp; metabolism case reports
2025

Partial adrenalectomy for pheochromocytoma in the multiple endocrine neoplasia type 2 population: Time to reconsider?

Surgery
2025

Beyond Hypertension: Hypoglycemia as an Atypical Presentation of Pheochromocytoma in Neurofibromatosis Type 1.

Cureus
2025

Multicentric B-cell lymphoma, phaeochromocytoma and amyloid-rich thyroid carcinoma in a common warthog (Phacochoerus africanus): a case of multiple endocrine neoplasia type 2?

Journal of comparative pathology
2025

MEN2: surgical precision in the era of precision medicine.

Endocrine-related cancer
2025

Kinome profiling reveals pathogenic variant specific protein signalling networks in MEN2 children with Medullary Thyroid Cancer.

NPJ precision oncology
2025

An Analysis of Primary Hyperparathyroidism in Individuals Diagnosed with Multiple Endocrine Neoplasia Type 2.

Diseases (Basel, Switzerland)
2025

Population Prevalence of the Major Thyroid Cancer-Associated Syndromes.

The Journal of clinical endocrinology and metabolism
2025

Genomic testing for RET in the clinic: UK and global perspective.

Endocrine-related cancer
2025

Hereditary Medullary Thyroid Cancer: Genotype-Phenotype Correlation.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer
2025

Epidemiology, Clinical Presentation, and Diagnosis of Medullary Thyroid Carcinoma.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer
2025

Thyroid C-Cell Biology and Oncogenic Transformation.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer
2025

Histopathology of C Cells and Medullary Thyroid Carcinoma.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer
2025

What Is New in Diagnostics and Management of Medullary Thyroid Carcinoma.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer
2025

RET C611Y Germline Variant in Multiple Endocrine Neoplasia Type 2A in Denmark 1930-2021: A Nationwide Study.

Cancers
2024

Medullary thyroid cancer in MEN2 pediatric/adolescent carriers of RET mutation: genotype/phenotype correlation and outcome in a retrospective series of 23 patients.

Frontiers in oncology
2024

Prevalence of the major thyroid cancer-associated syndromes in the United States.

medRxiv : the preprint server for health sciences
2025

Mechanisms of resistance to RET-directed therapies.

Endocrine-related cancer
2025

Efficacy and Safety of Selective RET Inhibitors in Patients with Advanced Hereditary Medullary Thyroid Carcinoma.

Thyroid : official journal of the American Thyroid Association
2024

Endocrine Perspective of Cutaneous Lichen Amyloidosis: RET-C634 Pathogenic Variant in Multiple Endocrine Neoplasia Type 2.

Clinics and practice
2024

Pregnancy After Beating Thyroid Cancer: A Case Series.

Cureus
2025

Multiple linear papules in a 68-year-old man.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
2024

A Case of Cushing's Disease and a RET Pathogenic Variant: Exploring Possible Rare Associations.

Cureus
2024

Molecular diagnostic approaches in detecting rearranged during transfection oncogene mutations in multiple endocrine neoplasia type 2.

World journal of clinical cases
2025

Living with a RET gene mutation: patient perspectives.

Endocrine-related cancer
2024

Anesthesia Management in Hereditary Pheochromocytoma and Paraganglioma: Updated Insights into Clinical Features and Perioperative Care.

Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih
2024

Pheochromocytoma-Paraganglioma Syndrome: A Multiform Disease with Different Genotype and Phenotype Features.

Biomedicines
2025

Cellular mechanisms of RET receptor dysfunction in multiple endocrine neoplasia 2.

Endocrine-related cancer
2024

Genotype/phenotype correlations in multiple endocrine neoplasia type 2.

Endocrine-related cancer
2025

Nursing care during management of recurrent pheochromocytoma: A case study.

Nursing in critical care
2024

Thyroid Malignancy and Cutaneous Lichen Amyloidosis: Key Points Amid RET Pathogenic Variants in Medullary Thyroid Cancer/Multiple Endocrine Neoplasia Type 2 (MEN2).

International journal of molecular sciences
2024

The Long-Term Cure of Patients With Hereditary Medullary Thyroid Carcinoma: 40 Years of Follow-Up in a Single Center.

Deutsches Arzteblatt international
2024

MEN2 phenotype in a family with germline heterozygous rare RET K666N variant.

Endocrinology, diabetes &amp; metabolism case reports
2024

Medullary Thyroid Carcinoma: A Unique Case Report.

Cureus
2024

Ganglioneuromatous polyposis associated with type 2 B multiple endocrine neoplasia (MEN 2B) - case report.

Annals of agricultural and environmental medicine : AAEM
2024

Critically evaluated key points on hereditary medullary thyroid carcinoma.

Frontiers in endocrinology
2024

C634Y mutation in RET-induced multiple endocrine neoplasia type 2A: A case report.

World journal of clinical cases
2024

[30 years of prophylactic thyroidectomy for hereditary medullary thyroid cancer : A milestone in translational medicine].

Chirurgie (Heidelberg, Germany)
2024

Two sisters diagnosed with familial paraganglioma syndrome type 1 (FPGL1) and multiple endocrine neoplasia type 2A (MEN2A).

World journal of surgical oncology
2024

Genotype-specific development of MEN 2 constituent components in 683 RET carriers.

Endocrine-related cancer
2024

A comparative analysis of surgically excised hereditary and sporadic pheochromocytomas: Insights from a single-center experience.

The Kaohsiung journal of medical sciences
2024

A case report of multiple endocrine neoplasia type 2B.

Annals of medicine and surgery (2012)
2025

Clinical Activity of Selpercatinib in RET-mutant Pheochromocytoma.

The Journal of clinical endocrinology and metabolism
2024

Management of Type 2 Diabetes Mellitus With Noninsulin Pharmacotherapy.

American family physician
2024

Current prospects of hereditary adrenal tumors: towards better clinical management.

Hereditary cancer in clinical practice
2024

Accelerated MEN2A in homozygous RET carriers in the context of consanguinity.

European journal of endocrinology
2024

RET 634 germline/gonadal mosaicism generating a second pathogenic amino acid change in multiple endocrine neoplasia type 2A.

American journal of medical genetics. Part A
2023

Multiple endocrine neoplasia type 2 - solving the puzzle.

Journal of family medicine and primary care
2024

Does Genotype-Specific Phenotype in Patients with Multiple Endocrine Neoplasia Type 2 Occur as Current Guidelines Predict?

Cancers
2023

Simultaneous Occurrence of Medullary Thyroid Carcinoma and Papillary Thyroid Carcinoma: A Case Series with Literature Review.

Current oncology (Toronto, Ont.)
2023

Clinical characteristics of a large familial cohort with Medullary thyroid cancer and germline Cys618Arg RET mutation in an Israeli multicenter study.

Frontiers in endocrinology
2024

Multiple endocrine neoplasia type 2: towards a risk-based approach integrating molecular and biomarker results.

Current opinion in oncology
2023

[Surgical treatment of pheochromocytoma].

Problemy endokrinologii
2023

Molecular Basis and Natural History of Medullary Thyroid Cancer: It is (Almost) All in the RET.

Cancers
2023

Clinical presentation of MEN 2A in index vs. non-index patients.

Endocrine
2023

RET Proto-Oncogene Variants in Patients with Medullary Thyroid Carcinoma from the Mediterranean Basin: A Brief Report.

Life (Basel, Switzerland)
2023

Adefovir Dipivoxil as a Therapeutic Candidate for Medullary Thyroid Carcinoma: Targeting RET and STAT3 Proto-Oncogenes.

Cancers
2022

Simultaneous bilateral laparoscopic cortical-sparing adrenalectomy for bilateral pheochromocytomas in multiple endocrine neoplasia type 2.

Frontiers in surgery
2023

Genetic Study in Pheochromocytoma: Is It Possible to Stratify the Risk of Hereditary Pheochromocytoma?

Neuroendocrinology
2023

RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectives.

Pharmacology &amp; therapeutics
2022

Progressive metastatic pheochromocytoma induced by multiple endocrine neoplasia type 2A with a lethal outcome.

IJU case reports
2022

[The trends in early precision diagnosis and treatment strategies of multiple endocrine neoplasia type 2].

Zhonghua wai ke za zhi [Chinese journal of surgery]
2022

Multiple endocrine neoplasia type 2 (MEN2) and RET specific modifications of the ACMG/AMP variant classification guidelines and impact on the MEN2 RET database.

Human mutation
2022

Synchronized Laparoscopic Bilateral Adrenalectomy for Pheochromocytoma in Multiple Endocrine Neoplasia Syndrome: A Case Report.

Journal of kidney cancer and VHL
2022

A Case Study of Multiple Endocrine Neoplasia Type 2A.

Cureus
2023

Elevated Calcitonin Levels in a Patient With a Pheochromocytoma: A Case Report.

The American surgeon
2022

Management of medullary carcinoma of the thyroid: a review.

The Journal of international medical research
2022

MEN2B Masquerading as Postural Orthostatic Tachycardia Syndrome.

JACC. Case reports
2022

Psychosocial Characteristics and Experiences in Patients with Multiple Endocrine Neoplasia Type 2 (MEN2) and Medullary Thyroid Carcinoma (MTC).

Children (Basel, Switzerland)
2022

Pheochromocytoma triggered by coronavirus disease 2019: a case report.

Journal of medical case reports
2022

Multiple endocrine neoplasia type 2 and autoimmune polyendocrine syndromes (type 1 diabetes mellitus and Graves' disease) in a 16-year-old male with Kabuki syndrome.

Endocrine journal
2022

RET receptor signaling: Function in development, metabolic disease, and cancer.

Proceedings of the Japan Academy. Series B, Physical and biological sciences
2022

Multiple endocrine neoplasia 2: an overview.

Therapeutic advances in chronic disease
2022

Cancer predisposing syndrome: a retrospective cohort analysis in a pediatric and multidisciplinary genetic cancer counseling unit.

International journal of clinical oncology
2023

Male gender as a poor prognostic factor in medullary thyroid carcinoma: behavior or biological difference?

Minerva endocrinology
2021

Germline RET Leu56Met Variant Is Likely Not Causative of Multiple Endocrine Neoplasia Type 2.

Frontiers in endocrinology
2022

Clinical features and signaling effects of RET D631Y variant multiple endocrine neoplasia type 2 (MEN2).

The Korean journal of internal medicine
2021

[Medullary thyroid carcinoma: current clinical progress].

Deutsche medizinische Wochenschrift (1946)
2021

Laparoscopic resection of aortocaval paraganglioma diagnosed by serial increase in urinary metanephrines after bilateral adrenalectomy in a patient with multiple endocrine neoplasia type 2A.

IJU case reports
2021

Treatment outcome with a selective RET tyrosine kinase inhibitor selpercatinib in children with multiple endocrine neoplasia type 2 and advanced medullary thyroid carcinoma.

European journal of cancer (Oxford, England : 1990)
2021

Pheochromocytoma as a rare hypertensive complication rarely associated with pregnancy: Diagnostic difficulties (Review).

Experimental and therapeutic medicine
2021

Calcitonin and complementary biomarkers in the diagnosis of hereditary medullary thyroid carcinoma in children and adolescents.

Journal of pediatric endocrinology &amp; metabolism : JPEM
2021

Medullary thyroid carcinoma with diabetic ketoacidosis: an autopsy case report and literature review.

Forensic science, medicine, and pathology
2021

Surgical Remission of Diabetes in a Patient With Mutation of RET Proto-Oncogene.

AACE clinical case reports
2021

Multiple endocrine neoplasia type 2: diagnostic challenges of a medullary thyroid carcinoma nodule.

Internal medicine journal
2021

Procalcitonin measured by three different assays is an excellent tumor marker for the follow-up of patients with medullary thyroid carcinoma.

Clinical chemistry and laboratory medicine
2021

Acute coronary syndrome: Uncommon presentation of multiple endocrine neoplasia.

International journal of surgery case reports
2021

Spectrum of Germline RET variants identified by targeted sequencing and associated Multiple Endocrine Neoplasia type 2 susceptibility in China.

BMC cancer
2022

Multiple endocrine neoplasia type 2: A review.

Seminars in cancer biology
2021

[A young male with multiple endocrine neoplasia type 2 misdiagnosed as viral myocarditis].

Zhonghua xin xue guan bing za zhi
2021

Pheochromocytoma in Multiple Endocrine Neoplasia Type 2.

Mayo Clinic proceedings
2020

Multiple endocrine neoplasia type 2B: A report of a rare case.

Journal of oral and maxillofacial pathology : JOMFP
2021

Homozygosity for the pathogenic RET hotspot variant p.Cys634Trp: A consanguineous family with MEN2A.

European journal of medical genetics
2021

RMRP, RMST, FTX and IPW: novel potential long non-coding RNAs in medullary thyroid cancer.

Orphanet journal of rare diseases
2021

A rare RET mutation in an Indian pedigree with familial medullary thyroid carcinoma.

Indian journal of cancer
2021

Diagnostic RET genetic testing in 1,058 index patients: A UK centre perspective.

Clinical endocrinology
2020

Ruptured functioning adrenal tumour, atypical presentation with renal colic and hypertension.

BMJ case reports
2020

Updates in the advances of sporadic medullary thyroid carcinoma: from the molecules to the clinic.

Gland surgery
2021

Positron Emission Tomography Imaging in Medullary Thyroid Carcinoma: Time for Reappraisal?

Thyroid : official journal of the American Thyroid Association
2021

Impact of gastrointestinal symptoms on quality of life in MEN2.

Clinical endocrinology
2020

Roles of the RET Proto-oncogene in Cancer and Development.

JMA journal
2020

[Surgical aspects of multiple endocrine neoplasia type 2].

Therapeutische Umschau. Revue therapeutique
2021

A novel germline variant in RET gene resulting in an additional cysteine in a family with familial medullary thyroid carcinoma.

Familial cancer
2020

5P Strategies for Management of Multiple Endocrine Neoplasia Type 2: A Paradigm of Precision Medicine.

Frontiers in endocrinology
2020

A New MEN2 Syndrome with Clinical Features of Both MEN2A and MEN2B Associated with a New RET Germline Deletion.

Case reports in endocrinology
2020

Medullary Thyroid Carcinoma in a Patient with MEN 1 Syndrome. Case Report and Literature Review.

OncoTargets and therapy
2020

Thyroid surgery in 103 children in a single institution from 2000-2014.

Annals of Saudi medicine
2021

Vandetanib in a Child Affected by Neurofibromatosis Type 1 and Medullary Thyroid Carcinoma with Both NF1 and Homozygous RET Proto-oncogen Germ-line Mutations.

Journal of clinical research in pediatric endocrinology
2020

[Medullary thyroid carcinoma and multiple endocrine neoplasia type 2].

Deutsche medizinische Wochenschrift (1946)
2021

A Novel Double RET E768D/L790F Mutation Associated with a MEN2B-Like Phenotype.

Thyroid : official journal of the American Thyroid Association
2020

HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: History of the multiple endocrine neoplasia workshops and overview of MEN2019.

Endocrine-related cancer
2020

A Proposed Grading Scheme for Medullary Thyroid Carcinoma Based on Proliferative Activity (Ki-67 and Mitotic Count) and Coagulative Necrosis.

The American journal of surgical pathology
2020

Variability in Medullary Thyroid Carcinoma in RET L790F Carriers: A Case Comparison Study of Index Patients.

Frontiers in endocrinology
2020

MEN2-related pheochromocytoma: current state of knowledge, specific characteristics in MEN2B, and perspectives.

Endocrine
2020

Update on the Treatment of Medullary Thyroid Carcinoma in Patients with Multiple Endocrine Neoplasia Type 2.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
2020

Identifying novel oncogenic RET mutations and characterising their sensitivity to RET-specific inhibitors.

Journal of medical genetics
2020

State-of-the-Art Strategies for Targeting RET-Dependent Cancers.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2019

A primer on the genetics of medullary thyroid cancer.

Current oncology (Toronto, Ont.)
2019

RET in breast cancer: pathogenic implications and mechanisms of drug resistance.

Cancer drug resistance (Alhambra, Calif.)
2019

Medullary thyroid carcinoma with double negative calcitonin and CEA: a case report and update of literature review.

BMC endocrine disorders
2019

Risk factors of post-surgery complications in children with thyroid cancer.

International journal of pediatric otorhinolaryngology
2020

Children are at a high risk of hypocalcaemia and hypoparathyroidism after total thyroidectomy.

Journal of pediatric surgery
2019

RET S409Y Germline Mutation and Associated Medullary Thyroid Carcinoma.

Thyroid : official journal of the American Thyroid Association
2019

Germline BRCA1 Mutation Detected in a Multiple Endocrine Neoplasia Type 2 Case With RET Codon 634 Mutation.

Frontiers in genetics
2019

Surgical Management of Multiple Endocrine Neoplasia 1 and Multiple Endocrine Neoplasia 2.

The Surgical clinics of North America
2019

[Large bowel ganglioneuromatosis associated with neurofibromatosis type 1].

Annales de pathologie
2019

Present status of prophylactic thyroidectomy in pediatric multiple endocrine neoplasia 2: a nationwide survey in Japan 1997-2017.

Journal of pediatric endocrinology &amp; metabolism : JPEM
2019

Long-Term Outcomes and Aggressiveness of Hereditary Medullary Thyroid Carcinoma: 40 Years of Experience at One Center.

The Journal of clinical endocrinology and metabolism
2019

Quality of Life and Coping in Multiple Endocrine Neoplasia Type 2.

Journal of the Endocrine Society
2019

Calcitonin measurement in pediatrics: reference ranges are gender-dependent, validation in medullary thyroid cancer and thyroid diseases.

Clinical chemistry and laboratory medicine
2019

Genotype and phenotype landscape of MEN2 in 554 medullary thyroid cancer patients: the BrasMEN study.

Endocrine connections
2018

[Familial medullary thyroid carcinoma: case report and literature review.].

Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina)
2019

[Genetics of pheochromocytoma and the relevance in surgery].

Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
2018

Update on Multiple Endocrine Neoplasia Type 2: Focus on Medullary Thyroid Carcinoma.

Journal of the Endocrine Society
2018

Utilization of Genetic Testing for RET Mutations in Patients with Medullary Thyroid Carcinoma: a Single-Center Experience.

Journal of genetic counseling
2019

Secondary findings from next-generation sequencing: what does actionable in childhood really mean?

Genetics in medicine : official journal of the American College of Medical Genetics
2018

A case of pheochromocytoma with negative MIBG scintigraphy, PET-CT and genetic tests (VHL included) and a rare case of post-operative erectile dysfunction.

Hormones (Athens, Greece)
2018

Prophylactic thyroidectomy in children with multiple endocrine neoplasia type 2.

The British journal of surgery
2018

[Molecular Targeted Therapies for Hereditary Cancer Syndrome].

Gan to kagaku ryoho. Cancer &amp; chemotherapy
2018

Concurrent primary hyperparathyroidism and pheochromocytoma in a Chinese lady with neurofibromatosis type 1.

Endocrinology, diabetes &amp; metabolism case reports
2017

Medullary thyroid cancer, leukemia, mesothelioma and meningioma associated with germline APC and RASAL1 variants: a new syndrome?

Hormones (Athens, Greece)
2018

Medullary Thyroid Carcinoma: Survival Analysis and Evaluation of Mutation-Specific Immunohistochemistry in Detection of Sporadic Disease.

World journal of surgery
2018

Multiple endocrine neoplasia 2 in Cyprus: evidence for a founder effect.

Journal of endocrinological investigation
2018

Preimplantation Genetic Diagnosis of Multiple Endocrine Neoplasia Type 2A Using Informative Markers Identified by Targeted Sequencing.

Thyroid : official journal of the American Thyroid Association
2018

[A Case of Rectal Cancer with Multiple Endocrine Neoplasia Type 2].

Gan to kagaku ryoho. Cancer &amp; chemotherapy
2018

Non-mammalian models of multiple endocrine neoplasia type 2.

Endocrine-related cancer
2018

Novel targeted therapeutics for MEN2.

Endocrine-related cancer
2018

The evolving clinical, genetic and therapeutic landscape of multiple endocrine neoplasia type 2.

Endocrine-related cancer
2018

Extent of surgery for phaeochromocytomas in the genomic era.

The British journal of surgery
2018

Prophylactic thyroidectomies in MEN2 syndrome: Management and outcomes.

Journal of pediatric surgery
2018

Pathology and genetics of phaeochromocytoma and paraganglioma.

Histopathology
2017

Functional analysis of RET with multiple endocrine neoplasia type 2.

Journal of cancer research and therapeutics
2018

Structure and function of RET in multiple endocrine neoplasia type 2.

Endocrine-related cancer
2018

Patient quality of life and prognosis in multiple endocrine neoplasia type 2.

Endocrine-related cancer
2017

Dermal Hyperneury and Multiple Sclerotic Fibromas in Multiple Endocrine Neoplasia Type 2A Syndrome.

JAMA dermatology
2017

Detection of early stage medullary thyroid carcinoma by measuring serum calcitonin using an electro chemiluminescence immuno-assay: A case report of a young Japanese woman with a high-risk RET mutation.

Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology
2016

Positive Germline Selection in Pedigrees With Multiple Endocrine Neoplasia Type 2 Carrying V804M Mutation in the RET Gene.

World journal of oncology
2017

Nationwide French Study of RET Variants Detected from 2003 to 2013 Suggests a Possible Influence of Polymorphisms as Modifiers.

Thyroid : official journal of the American Thyroid Association
2017

A large Chinese pedigree of multiple endocrine neoplasia type 2A with a novel C634Y/D707E germline mutation in RET exon 11.

Oncology letters
2018

RET-mediated modulation of tumor microenvironment and immune response in multiple endocrine neoplasia type 2 (MEN2).

Endocrine-related cancer
2017

Perioperative outcomes of syndromic paraganglioma and pheochromocytoma resection in patients with von Hippel-Lindau disease, multiple endocrine neoplasia type 2, or neurofibromatosis type 1.

Surgery
2018

Advances in risk-oriented surgery for multiple endocrine neoplasia type 2.

Endocrine-related cancer
2017

Bilateral pheochromocytoma with ganglioneuroma component associated with multiple neuroendocrine neoplasia type 2A: a case report.

Journal of medical case reports
2018

No calcitonin change in a person taking dulaglutide diagnosed with pre-existing medullary thyroid cancer.

Diabetic medicine : a journal of the British Diabetic Association
2017

Clinical Features of a Family with Multiple Endocrine Neoplasia Type 2A Caused by the D631Y RET Mutation.

Thyroid : official journal of the American Thyroid Association
2017

Is new American Thyroid Association risk classification for hereditary medullary thyroid carcinoma applicable to Chinese patients? A single-center study.

Chinese journal of cancer research = Chung-kuo yen cheng yen chiu
2017

Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness.

The Journal of clinical endocrinology and metabolism
2017

Phaeochromocytoma in multiple endocrine neoplasia type 2: RET codon-specific penetrance and changes in management during the last four decades.

Clinical endocrinology
2017

Genetics of Multiple Endocrine Neoplasia Type 1/Multiple Endocrine Neoplasia Type 2 Syndromes.

Endocrinology and metabolism clinics of North America
2017

Genotype-Phenotype Correlation in Patients With Germline Mutations of VHL, RET, SDHB, and SDHD Genes: Thai Experience.

Clinical medicine insights. Endocrinology and diabetes
2017

PRECISION MEDICINE: AN UPDATE ON GENOTYPE/BIOCHEMICAL PHENOTYPE RELATIONSHIPS IN PHEOCHROMOCYTOMA/PARAGANGLIOMA PATIENTS.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
2017

FDOPA Patterns in Adrenal Glands: A Pictorial Essay.

Clinical nuclear medicine
2017

Assessment of Depression, Anxiety, Quality of Life, and Coping in Long-Standing Multiple Endocrine Neoplasia Type 2 Patients.

Thyroid : official journal of the American Thyroid Association
2017

[The trends in early diagnosis and treatment strategies of multiple endocrine neoplasia type 2: practice, dilemma and prospective].

Zhonghua yi xue za zhi
2017

Search of the p.M918T Mutation in the RET Oncogene in Mexican Adult Patients with Medullary Thyroid Carcinoma.

Experimental and clinical endocrinology &amp; diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
2016

Anesthetic Management of Clinically Silent Familial Pheochromocytoma with MEN 2A: A Report of Four Cases.

The Indian journal of surgery
2016

[Study of Medullary Thyroid Carcinoma from a proband].

Archivos argentinos de pediatria
Ver todos os 278 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Neoplasias endócrinas múltiplas tipo 2.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Neoplasias endócrinas múltiplas tipo 2

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. How has genetics changed the diagnosis and care of multiple endocrine neoplasia type 2? The merits and pitfalls of a genetic-based diagnostic and therapeutic approach.
    Annales d'endocrinologie· 2026· PMID 41866073mais citado
  2. Advanced disease and biochemical phenotype shift in multiple endocrine neoplasia type 2A-related pheochromocytoma.
    JCEM case reports· 2026· PMID 41837230mais citado
  3. Systematic structure-based analysis of RET variants in MEN2A, Hirschsprung's disease, and their paradoxical co-occurrence.
    Disease models &amp; mechanisms· 2026· PMID 41816802mais citado
  4. Bilateral pheochromocytoma: case series and review of treatment strategies based on genetic mutations.
    Translational andrology and urology· 2026· PMID 41809780mais citado
  5. Rare cases in two Chinese MEN2A families with RET C634Y germline mutation-a homozygous female patient and heterozygous identical twins: a systematic review of literature.
    Frontiers in endocrinology· 2026· PMID 41727686mais citado

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:653(Orphanet)
  2. MONDO:0019003(MONDO)
  3. GARD:3830(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q56014243(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Neoplasias endócrinas múltiplas tipo 2
Compêndio · Raras BR

Neoplasias endócrinas múltiplas tipo 2

ORPHA:653 · MONDO:0019003
Prevalência
1-9 / 100 000
Herança
Autosomal dominant
CID-10
D44.8 · Neoplasia de comportamento incerto ou desconhecido com comprometimento pluriglandular
CID-11
Ensaios
4 ativos
Início
Adolescent, Adult, Childhood, Infancy
Prevalência
2.9 (Europe)
MedGen
UMLS
C0025268
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades